HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific...
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma )
Also on site :
- PHOTO COLLECTION: Menendez Brothers
- Disneyland raises hopes for future Toy Story Midway Mania makeovers
- Thumbprint on cigarette carton leads to arrest in 1977 death of young woman